title: Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
abstract: BACKGROUND
  To report our prospective experience on the incidence and pattern of oxaliplatin (OXA)-induced peripheral neuropathy (OXA-IPN) in patients with colorectal cancer (CRC) treated with either FOLFOX-4 or XELoda + OXaliplatin (XELOX).
  
  
  METHODS
  One hundred and fifty patients scheduled to be treated with either FOLFOX or XELOX for CRC were prospectively monitored at baseline and followed-up during chemotherapy. The incidence and severity of symptoms secondary to OXA-IPN were recorded using three different types of assessment, i.e. the motor and neurosensory National Cancer Institute common toxicity criteria, version 3.0 (NCI-CTCv3), the clinical version of the total neuropathy score (TNSc) and electrophysiological scores.
  
  
  RESULTS
  Patients treated with either FOLFOX-4 or XELOX manifested similar incidence rates and severities of acute OXA-IPN. However, FOLFOX-4 was associated with increased incidence of chronic neurotoxicity, compared with XELOX-treated patients (n = 64/77 versus 44/73; P = 0.002), at a very similar OXA median cumulative dose during both regimens. Both the NCI-CTCv3 and TNSc demonstrated that the severity of cumulative OXA-IPN in FOLFOX-4-treated patients is higher than in those treated with XELOX.
  
  
  CONCLUSIONS
  The incidence of acute neurotoxicity during FOLFOX-4 therapy is similar to XELOX. However, it seems that FOLFOX-4 is more neurotoxic than XELOX in terms of cumulative OXA-IPN, despite comparable OXA cumulative dose.
authors.affiliation: Department of Neurology, 'Saint Andrew's" State General Hospital of Patras, Patras; Department of Medicine-Division of Clinical Oncology, University Hospital of Patras, Rion-Patras, Greece.
authors.forename: A A
authors.initials: AA
authors.lastname: Argyriou
authors.affiliation: Department of Neurology-Unit of Neuro-Oncology, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Velasco
authors.affiliation: Department of Neurosciences, University of Padova, Padova.
authors.forename: C
authors.initials: C
authors.lastname: Briani
authors.affiliation: Department of Neuroscience and Biomedical Technology, University of Milan-Bicocca, Monza.
authors.forename: G
authors.initials: G
authors.lastname: Cavaletti
authors.affiliation: Department of Neurology-Unit of Neuro-Oncology, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Bruna
authors.affiliation: Department of Neuroscience and Biomedical Technology, University of Milan-Bicocca, Monza.
authors.forename: P
authors.initials: P
authors.lastname: Alberti
authors.affiliation: Data Medica Group, EMG Unit, CEMES, Padova.
authors.forename: M
authors.initials: M
authors.lastname: Cacciavillani
authors.affiliation: Oncology Unit 1, Veneto Oncology Institute - IRCCS, Padova, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Lonardi
authors.affiliation: Department of Oncology-Unit of Colorectal Cancer, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Santos
authors.affiliation: Department of Oncology, S. Gerardo Hospital, Monza, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Cortinovis
authors.affiliation: Department of Oncology, S. Gerardo Hospital, Monza, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Cazzaniga
authors.affiliation: Department of Neurology-Unit of Neuro-Oncology, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain. Electronic address: kalofonos@upatras.gr.
authors.forename: H P
authors.initials: HP
authors.lastname: Kalofonos
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000453:epidemiology*; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010071:Oxaloacetates; D011446:Prospective Studies
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil